Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer
Abstract
To identify clinically relevant mechanisms of resistance to ER-directed therapies in ER+ breast cancer.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 13, 2020
- Source ID
- 10.1158/1078-0432.ccr-19-3958
Entities
People
- Adrienne G Waks
- Aviv Regev
- David E Root
- Eric Winer
- Federica Piccioni
- Jon H Chung
- Jorge E. Buendia-buendia
- Justin G. Kusiel
- Kailey J. Kowalski
- Michael S Cuoco
- Nancy U Lin
- Nikhil Wagle
- Ofir Cohen
- Orit Rozenblatt-Rosen
- Pedro Exman
- Pingping Mao
- Samuel S Freeman
- Seth A. Wander
- Utthara Nayar
- Vincent A. Miller
Organizations
- American Association for Cancer Research
- Brigham and Women's Hospital
- Dana Farber Harvard Cancer Center
- Dana–Farber Cancer Institute
- Massachusetts Institute of Technology
- Susan G. Komen for the Cure
- United States Department of Defense